ArticleBMC genomics2025
MEGDTA: multi-modal drug-target affinity prediction based on protein three-dimensional structure and ensemble graph neural network.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predicting Enzyme pH Optima from Structure Using Equivariant Graph Neural Networks.Journal of chemical information and modeling · 2026Article
- SCAD-DTA: spherical concept alignment with dynamic multi-modal fusion for drug-target affinity prediction.Molecular diversity · 2026Article
- Dynamics-enhanced molecular property prediction guided by deep learning.PLoS computational biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDrug development is a time-consuming and costly endeavor, and utilizing computer-aided methods to predict drug-target affinity (DTA) can significantly accelerate this process. The key to accurate DTA prediction lies in selecting appropriate computational models to effectively extract features from drug molecular structures and target protein structures. Existing methods usually ignore the features of the protein three-dimensional structure.
resultsThis paper proposes a multi-modal drug-target affinity prediction model based on protein three-dimensional structure and ensemble graph neural networks (MEGDTA). This model aims to capture diverse features from drug and target structure using neural network architectures, especially for protein three-dimensional structure. First, one drug is represented into two forms by a molecular graph and a Morgan Fingerprint, and their features are extracted by constructing a graph feature space and a fully connected network, respectively. Second, for a protein, a residue graph is constructed based on its three-dimensional structure. And, the protein sequence and residue graph are processed using a long short-term memory (LSTM) network and multiple parallel graph neural networks (GNNs) with variant modules to learn the latent features of proteins. Third, a cross-attention mechanism fuses the extracted features of the drug and protein, followed by fully connected layers to finalize the prediction. The source code of MEGDTA is available from https://github.com/liyijuncode/MEGDTA .
conclusionsMEGDTA is validated on three publicly available benchmark datasets, Davis, KIBA and Metz. A comparative study is conducted with other existing models. The results show that MEGDTA performs strongly in terms of mean squared error (MSE) and concordance index (CI), and r
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.